Biofrontera Inc. Provides Preliminary Revenue Guidance for the Second Quarter, First Half and Full-Year of 2023
For the first half, the company anticipated revenue to be in the range of approximately $14.4 million to $14.6 million, representing growth of approximately 1% to 3% compared with the first half of 2022.
For the full year, the company affirms its previously announced expectations for full-year 2023 growth in revenue to be at least 25% compared with 2022.